Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

01:50 EDT 28th July 2015 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 12,000+

Extremely Relevant

Developing a Vaccine for the Epstein-Barr Virus Could Prevent Up To 200,000 Cancers Globally, Say Experts

A vaccine to prevent infection with a common herpes virus, the Epstein-Barr Virus (EBV), could help prevent up to 200,000 new cancers worldwide per year, say Cancer Research UK experts to mark the 50th anniversary of EBV’s discovery, today

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus– speci...

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specif...

Viral protein helps Epstein-Barr virus-infected B cells escape human killer T cells

About 90 percent of adults worldwide are infected with Epstein-Barr virus, or EBV. The virus infects B cells (the white blood cells that make antibodies) and can contribute to B-cell-derived cancers, but in most people it remains dormant -- a state s...

Epstein-Barr virus co-infection may boost malaria mortality in childhood

Malaria researchers are calling attention to a trouble-maker whose effects may be underappreciated: Epstein-Barr virus (EBV). Their experiments with mice show that co-infection with a virus closely related to EBV can make a survivable malaria parasit...

Researchers shed light on link between diet, Epstein-Barr

A new study is shedding light on the connection between diet and a common childhood disease. Using national health data, the researchers determined children who ate certain types of food or dealt with food insecurity may be more likely to contract th...

Scientists Discover How the Epstein-Barr Virus Hides in Human Cells

Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immune system is the viral protein LMP2A. As published in the scientific journal PLOS Pathogens, the protein helps EBV-infected cells hide from T cells. This camouflage through

Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein–Barr virus as a potential vaccine and diagnostic agent

In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures

How the Epstein-Barr virus hides in human cells

(Helmholtz Zentrum München - German Research Center for Environmental Health) Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immu...

Breakthrough Therapy Designation for EBV-Associated Lymphoproliferative Disease After HCT

The US Food and Drug Administration (FDA) is giving the green light to a new immunotherapy for patients who have rituximab-refractory, Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) following allogeneic hematopoietic cell transplantation (HCT).

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatme...

Case–control study of Epstein–Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease

New therapy from naive cells attacks high-risk viruses in cord blood transplant patients

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and the Texas Children's Hospital have expanded the use of virus-specific cell therapy in cord blood transplant patients to successfully prevent thre...

New therapy from naïve cells attacks high-risk viruses in cord blood transplant patients

Researchers have expanded the use of virus-specific cell therapy in cord blood transplant patients to successfully prevent three of the most problematic post-transplant viruses affecting this group of patients that have yet to be addressed clinically...

New therapy from naïve cells attacks high-risk viruses in cord blood transplant patients

(Baylor College of Medicine) Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and the Texas Children's Hospital have expanded the use of virus-specific cell therapy in cord blood transplant patients...

Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-01-29. This 56-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H1 2015’, provides an over...

A viral protein that helps EBV-infected B cells to escape human killer T cells

About 90% of adults worldwide are infected with Epstein-Barr virus, or EBV. The virus infects B cells (the white blood cells that make antibodies) and can contribute to B-cell-derived cancers, but in most people it remains dormant—a state scientist...

Cell Medica granted Orphan Drug designation for novel cellular therapy

Cell Medica announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr Virus (EBV) positive non-Hodgkin ...

Epstein–Barr virus BZLF1 protein impairs accumulation of host DNA damage proteins at damage sites in response to DNA damage

Atara gains on breakthrough designation

Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $0.92 to $20.48 after its partner, Memorial Sloan Kettering Cancer Center, received breakthrough therapy designation for EBV-CTL to treat rituximab-refractory lymphoproliferative disease associated with...

Orphan designation granted to Cell Medica's cancer drug

Cell Medica's novel immunotherapy CMD-003 received orphan drug status from the FDA for use in patients with Epstein-Barr viru -More- 

A single mutation helped last year's flu virus gain an advantage over the vaccine

(Cell Press) The 2014-2015 flu vaccine didn't work as well compared to previous years because the H3N2 virus recently acquired a mutation that concealed the infection from the immune system. A study published on June 25 in Cell Reports reveals the ma...

Why you need one vaccine for measles and many for the flu

While the influenza virus mutates constantly and requires a yearly shot that offers a certain percentage of protection, old reliable measles needs only a two-dose vaccine during childhood for lifelong immunity. A new study publishing May 21 in Cell R...

Wistar receives $5.6 million grant renewal from Wellcome Trust

(The Wistar Institute) The Wistar Institute and London-based global charity Wellcome Trust announce that they have signed a follow-on funding agreement of $5.6 over the next three years in support of ongoing research and development of a new class of...



Advertisement
 
Advertisement
 

News Quicklinks